CGN Nuclear Technology Returns to the European Association of Nuclear Medicine Annual Congress, Hejia Isotopes Debut on the Global Nuclear Medicine Stage

The 39th Annual Congress of the European Association of Nuclear Medicine was held in Vienna, Austria, from October 17 to 21. CGN Nuclear Technology appeared once again, continuing its participation since its first exhibition in 2025, and showcased the core medical isotope products of CGN Isotope (Mianyang) Technology Co., Ltd. The exhibition focused on CGN Hejia® Germanium-68 solution, Germanium-Gallium generator and supporting automatic elution device, while also introducing multiple medical isotope products such as Oxygen-18, Copper-64, Zirconium-89 and Iodine-123.

At this annual congress, physical exhibits such as the Germanium-Gallium generator and the supporting automatic elution device clearly presented the company's technical accumulation in key nuclide supply and supporting equipment research and development, attracting the attention of numerous nuclear medicine experts and industry representatives, who engaged in in-depth exchanges and discussions on product technical performance. The atmosphere was lively, and professionals highly praised the company's technical strength and product quality.

Experts and business representatives in the nuclear medicine field from Europe, Asia and North America visited the booth one after another, focusing on key issues such as production capacity assurance and introduction pathways for products including CGN Hejia® Germanium-68, the Germanium-Gallium generator and Oxygen-18. Multiple international partners showed strong interest in CGN Nuclear Technology's medical isotope product system and confirmed cooperation intentions, with preliminary discussions on possibilities such as long-term stable supply, joint technology research and development, and regional market coordination.

In the international exchanges from Barcelona to Vienna, CGN Nuclear Technology has continuously expanded its global market, with steady and firm progress. In the future, the company will focus on the development direction of “integrated diagnosis and treatment, precision targeting,” and is committed to building a comprehensive medical isotope industry system covering three levels: diagnosis, treatment and basic raw materials.

CGN Nuclear Technology plans to continue providing global customers with stable, reliable and high-quality diagnostic and therapeutic nuclide products, and to actively cooperate with upstream and downstream partners in the industry chain to jointly promote innovative research and development and clinical translation applications of radiopharmaceuticals, contributing to the development of the nuclear medicine field. The company hopes to further enhance its position in the global nuclear medicine field through continuous technological innovation and international cooperation.